Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib for NSCLC Harboring Activating EGFR Mutations in TKI naïve Patients
NCT05463224Phase 2Active, not recruiting
- Start
- Jan 2023
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of lazertinib in non-small cell lung cancer (NSCLC). Started Jan 2023; status: active, not recruiting.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05463224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05463224.